4Q 2020 Results and preliminary annual report

11. Feb 2021 | 2 min read

Moss, 11 February 2020

Gentian Diagnostics AS announces its results for the 4th quarter and 2020
preliminary annual results. The highlights include:

* Gentian finished the year with record sales of MNOK 17.2 in the 4Q20 which
corresponds to 22 % growth versus 4Q19

* Total sales revenue for the year was MNOK 63.3 representing a 32 % growth (22
% adjusted for currency effects) compared to the same period last year

* Double digit sales growth was achieved for all products and all regions in
2020

* Gentian’s unique PETIA-based SARS-CoV-2 antibody test has reached the next
development phase with an estimated launch by the end of 2021

* Encouraging scientific publications on GCAL® in context of COVID-19 patient
management have spurred the interest of hospitals and laboratories from all over
Europe

Please find the report and results presentation enclosed. The documents will
also be made available on www.gentian.com.

524428_GDAS Interim presentation 4Q 2020

524428_GDAS Interim Report 4Q 2020

For further information, please contact:

Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no 
Cell Phone: +47 919 05 242

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no 
Cell Phone. +47 919 06 525

 

You may also read


Feb 11, 2021 - Kristin Hart

4Q 2020 Results and preliminary annual report

Moss, 11 February 2020 Gentian Diagnostics AS announces its results for the 4th quarter and 2020 preliminary..

Jan 22, 2021 - Kristin Hart

SARS-CoV-2 antibody test moving to the next development phase

Moss, 22.01.2021 Gentian Diagnostics AS is pleased to announce that its high-throughput SARS-CoV-2 antibody..